ADPT
NEUTRALProductAdaptive Biotechnologies Corpor
This is the 2026-09-23 snapshot — the signals and analysis for ADPT as of this single trading day.
View full ADPT research hub →Analysis
ADPT is consolidating a massive structural breakout because the market is actively repricing its recurring revenue potential following a major clinical guideline shift. Recent news confirms that the NCCN updated its multiple myeloma guidelines to explicitly recommend ADPT's clonoSEQ assay for routine and repeat MRD testing, effectively cementing it as the standard of care. Despite headline noise from insider selling, the stock's PERFECT_STACK and MARKET_LEADER signals, combined with light 0.5x volume on the current pullback, confirm institutional accumulation and High-Conviction Price Discovery. Supported by a RISK_ON macro regime where equities are aggressively bidding up growth and ignoring rate pressures, this mild 2.5% dip from recent highs offers a highly constructive entry point.
Fired Signals
Key Takeaways
- Actionable Thesis: Use the current low-volume (0.5x) pullback to build a position, as the NCCN's explicit inclusion of clonoSEQ fundamentally expands ADPT's recurring revenue profile.
- Key Risk: Elevated valuation multiples and recent insider selling by C-suite executives could provide ammunition for short-sellers if broader market momentum stalls.
- What to Watch: Hold the $24.20 line-in-the-sand as the definitive risk level while looking toward upcoming earnings for proof of accelerated test volumes.